More importantly, ovarian cancer patients with exon 3 inclusion in the TCGA-OV cohort showed poor overall survival (Fig. 6n), implying that inclusion of BCL2L12 exon 3 may be involved in ovarian cancer progression. This evidence concerns the gene BCL2L12 and ovarian cancer.